SCHEMBL22497793

SCHEMBL22497793

CCOC(=O)c1cnc(Cl)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
ALOX15 P16050 1/20 0.45
ATR Q13535 1/20 0.43
MKNK2 Q9HBH9 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.41
SYK P43405 1/20 0.41
MAPK1 P28482 1/20 0.41
TP53 P04637 1/20 0.41
KDM4E B2RXH2 3/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
FOS P01100 1/20 0.39
JUN P05412 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29374417 1.00 ALDH1A1 (0.46) ALDH1A1ALOX15ATRMKNK2IRAK4
SCHEMBL12931891 0.88 ATR (0.47) ATRJUNNFKB1NFKB2RELA
SCHEMBL19493914 0.88 DGAT1 (0.43) ALDH1A1ALOX15ATRMKNK2KDM4E
SCHEMBL1521390 0.83 ALDH1A1 (0.43) ALDH1A1ALOX15IRAK4TP53KDM4E
SCHEMBL2446828 0.82 KDM4E (0.44) ALDH1A1ALOX15IRAK4TP53KDM4E
SCHEMBL31523140 0.82 ALDH1A1 (0.41) ALDH1A1ALOX15IRAK4MAPK1TP53
SCHEMBL30341786 0.81 ALDH1A1 (0.46) ALDH1A1ALOX15TP53KDM4EGAA
SCHEMBL502657 0.81 ALDH1A1 (0.46) ALDH1A1ALOX15TP53KDM4EGAA
SCHEMBL24950189 0.81 MERTK (0.42) ALOX15IRAK4MAPK1KDM4EMAPT
SCHEMBL24947721 0.81 MERTK (0.42) ALOX15IRAK4MAPK1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3947378-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2024-11-13 EP disclosed
US-20220218679-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2022-07-14 US disclosed
US-20220218679-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2022-07-14 US disclosed
EP-3947378-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS Galapagos N.V. (BE) 2022-02-09 EP disclosed
CN-113646305-A Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders 加拉帕戈斯股份有限公司 2021-11-12 CN disclosed
WO-2020200900-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2020-10-08 WO disclosed
WO-2020200900-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2020-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218679-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS LTB4R2, LTC4S, CYSLTR1 ALDH1A1 499/4885ALOX15 77/4885ATR 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.